- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04937283
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm With Micropapillary and Solid Subtype Negative by Intraoperative Frozen Sections: A Prospective and Multi-center Randomized Controlled Trial Study
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hang Su
- Phone Number: +86 13917810850
- Email: dreamsuhang@163.com
Study Contact Backup
- Name: Chang Chen, MD, PhD
- Phone Number: +86 021-65115006
- Email: chenthoracic@163.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China
- Recruiting
- Anhui Chest Hospital
-
Contact:
- Ning Xu
-
Hefei, Anhui, China
- Recruiting
- The First Affiliated Hospital of University of Science and Technology of China
-
Contact:
- Mingran Xie
-
-
Henan
-
Nanyang, Henan, China
- Recruiting
- Nanyang Central Hospital
-
Contact:
- Xinwei Dong
-
-
Jiangsu
-
Nantong, Jiangsu, China, 226001
- Recruiting
- Affiliated Hospital Of Nantong University
-
Contact:
- Honggang Ke
-
Nantong, Jiangsu, China, 216002
- Recruiting
- The Sixth People's Hospital of Nantong
-
Contact:
- Xuedong Zhang
-
Xuzhou, Jiangsu, China
- Recruiting
- Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Hao Xu
-
Yancheng, Jiangsu, China
- Recruiting
- Yancheng First People's Hospital
-
Contact:
- Jian Sun
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Shandong Public Health Clinical Center
-
Contact:
- Feng Jin
-
Sub-Investigator:
- Yunzeng Zhang
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Chang Chen, MD, PhD
- Phone Number: 2074 +86-021-65115006
- Email: chenthoracic@163.com
-
Shanghai, Shanghai, China
- Recruiting
- Huadong Hospital
-
Contact:
- Xiaoyong Shen
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Junqiang Fan
-
Huzhou, Zhejiang, China
- Recruiting
- Huzhou Central Hospital
-
Contact:
- Qibin Shen
-
Ningbo, Zhejiang, China
- Recruiting
- Ningbo First Hospital
-
Contact:
- Xinjian Li
-
Ningbo, Zhejiang, China
- Recruiting
- Ningbo No.2 Hospital
-
Contact:
- Guofang Zhao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient aged 20-79 years old, both male or female;
- Tumor size <= 2cm on preoperative CT scan;
- Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;
- Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);
- Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (<= 5%);
- Intraoperative frozen section indicated the resection margins was free of tumor cells;
- Lung function could withstand both lung segmentectomy and lobectomy (FEV1 > 1.5L or FEV1% >= 60%);
- Eastern Cooperative Oncology Group, 0 to 2;
- Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.
Exclusion Criteria:
- Radiological pure ground glass nodules (consolidation to tumor ratio < 0.25);
- The nodule is close to the lung hilus and is unable to perform segmentectomy;
- Intraoperative frozen section confirmed with micropapillary and solid subtype positive (> 5%);
- Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;
- Preoperative imaging examination or EBUS indicated lymph node positive metastasis;
- Preoperative imaging examination revealed distant metastasis;
- Patients with severe damage to heart, liver and kidney function (grade 3 ~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit);
- Patients with other malignant tumors;
- Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy);
- Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;
- Those who have participated in other tumor-related clinical trials within three months;
- Those are not suitable for participating in trials according to investigator's assessment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Segmentectomy with systemic lymph node dissection
Segmentectomy with hilar and mediastinal lymph node dissection is performed.
If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation.
As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed.
At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy.
When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
|
Segmentectomy with hilar and mediastinal lymph node dissection is performed.
If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed.
Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed.
At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
The distance from the dissection margin to the tumor edge must be evaluated intra-operatively.
If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
|
Active Comparator: Lobectomy with systemic lymph node dissection
lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery. |
Lobectomy with hilar and mediastinal lymph node dissection is performed.
Segmentectomy with hilar and mediastinal lymph node dissection is performed.
Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed.
At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
The distance from the dissection margin to the tumor edge must be evaluated intra-operatively.
If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recurrence-free survival rate
Time Frame: 5 year
|
Recurrence-free survival (RFS) was defined as the time from surgery until recurrence or death from any cause
|
5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 5 year
|
Overall survival (OS) was defined as the time from surgery until death from any cause
|
5 year
|
Operation time
Time Frame: 24 hours
|
The surgery time in both groups.
|
24 hours
|
Blood loss
Time Frame: 24 hours
|
Intraoperative blood loss in total.
|
24 hours
|
Incidence of operative complications
Time Frame: 1 month
|
Any intraoperative complications related to the surgery.
|
1 month
|
Post-operative respiratory function
Time Frame: 6 months
|
The post-operative respiratory function will be evaluated by FEV1% and FVC.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chang Chen, MD, PhD, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STAR001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.Active, not recruitingAdenocarcinoma of the LungChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingEGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IVChina
-
Meir Medical CenterUnknownAdenocarcinoma, Bronchiolo-Alveolar | Adenocarcinoma of the LungIsrael
-
Rambam Health Care CampusUnknownLung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
-
Intergroupe Francophone de Cancerologie ThoraciqueAstraZenecaCompletedPneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureFrance
-
Memorial Sloan Kettering Cancer CenterCompletedOligometastatic Lung AdenocarcinomaUnited States
-
Chinese PLA General HospitalUnknown
-
Zhou ChengzhiCompletedLung Adenocarcinoma Stage IVChina
-
Simcere Pharmaceutical Co., LtdUnknownAdvanced Primary Lung AdenocarcinomaChina
-
Wuhan Union Hospital, ChinaRecruitingLung Adenocarcinoma, Stage IChina
Clinical Trials on Segmentectomy with systemic lymph node dissection
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingLung AdenocarcinomaChina
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Tianjin Medical University Cancer Institute and...RecruitingLung Neoplasms | Lymph Node ExcisionChina
-
Eastern Hepatobiliary Surgery HospitalUnknownIntrahepatic CholangiocarcinomaChina
-
Sohag UniversityNot yet recruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Fujian Medical UniversityUnknown
-
Xiangyun ZongRecruitingBreast Cancer LymphedemaChina
-
Saint John's Cancer InstituteNational Institutes of Health (NIH)Completed
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female